[SCHEDULE 13G/A] Aldeyra Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Perceptive Advisors and affiliated parties report a 6.8% stake in Aldeyra Therapeutics (ALDX), representing 4,051,631 shares. The filing states the Master Fund directly holds the shares, with Perceptive Advisors as investment manager and Joseph Edelman as managing member, each deemed to beneficially own the shares. All reported shares reflect shared voting and dispositive power (no sole power). The ownership percentage is calculated using 59,895,588 outstanding shares of common stock as reported by the issuer. The filers certify the holdings were not acquired to influence control.

Positive

• Material disclosure of a 6.8% beneficial ownership stake in ALDX, improving transparency for investors
• Clear identification of reporting persons (Perceptive Advisors, Perceptive Life Sciences Master Fund, Ltd., Joseph Edelman) and their shared voting/dispositive power

Negative

• None.

Insights

Securities Analyst

TL;DR: A 6.8% passive stake by Perceptive indicates notable investor interest without claimed control intent.

Perceptive Advisors, its Master Fund, and Joseph Edelman together report beneficial ownership of 4,051,631 shares, equal to 6.8% of ALDX based on 59,895,588 shares outstanding. The filing indicates shared voting and dispositive power only, and includes the required certification that the position is not intended to change or influence control. For investors, this is a material disclosure of concentrated ownership by an active healthcare-focused investor group, though the report asserts a non-controlling purpose.

Corporate Governance Expert

TL;DR: Filing is a standard Schedule 13G/A disclosure showing significant but non-control-aligned ownership.

The Schedule 13G/A identifies the reporting persons and their relationships (investment manager and managing member) and clarifies that voting and disposition powers are shared. The explicit statement that the shares were not acquired to influence control and the certification signatures by Joseph Edelman follow regulatory norms for a 13G filing. This provides transparency on ownership concentration without signaling an activist campaign.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 13)

Aldeyra Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

01438T106

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 01438T106

1

Names of Reporting Persons

Perceptive Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,051,631.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,051,631.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,051,631.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 01438T106

1

Names of Reporting Persons

Joseph Edelman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,051,631.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,051,631.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,051,631.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP No. 01438T106

1

Names of Reporting Persons

Perceptive Life Sciences Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,051,631.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,051,631.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,051,631.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aldeyra Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 131 Hartwell Avenue, Suite 320,Lexington, MA 02421
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of Aldeyra Therapeutics, Inc. ("the Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
(c)	Citizenship: Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 01438T106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 59,895,588 outstanding shares of Common Stock as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2025. The Master Fund directly holds 4,051,631 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
(b)	Percent of class: Perceptive Advisors: 6.8% Mr. Edelman: 6.8% Master Fund, Ltd: 6.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(ii) Shared power to vote or to direct the vote: Perceptive Advisors: 4,051,631 Mr. Edelman: 4,051,631 Master Fund: 4,051,631
	(iii) Sole power to dispose or to direct the disposition of: Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0
	(iv) Shared power to dispose or to direct the disposition of: Perceptive Advisors: 4,051,631 Mr. Edelman: 4,051,631 Master Fund: 4,051,631
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Perceptive Advisors LLC

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

Joseph Edelman

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

Perceptive Life Sciences Master Fund, Ltd.

Signature:	/s/ Joseph Edelman
Name/Title:	Joseph Edelman, Managing Member
Date:	08/14/2025

FAQ

How many ALDX shares does Perceptive Advisors report owning?

The filers report beneficial ownership of 4,051,631 shares of Aldeyra Therapeutics common stock.

What percent of ALDX does the 4,051,631 shares represent?

The reported shares represent 6.8% of common stock based on 59,895,588 outstanding shares.

Who are the reporting persons in this Schedule 13G/A for ALDX?

The reporting persons are Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman.

Do the filers claim sole voting or dispositive power over the shares?

No. The filing reports 0 sole voting power and 4,051,631 shared voting and dispositive power for each reporting person.

Does the filing state an intent to influence control of Aldeyra Therapeutics?

The filers certify that the securities were not acquired and are not held to change or influence control of the issuer.